Cargando…
Plasma proteome in multiple sclerosis disease progression
BACKGROUND: The pathophysiology of multiple sclerosis disease progression remains undetermined. The aim of this study was to identify differences in plasma proteome during different stages of MS disease progression. METHODS: We used a multiplex aptamer proteomics platform (Somalogic) for sensitive d...
Autores principales: | Malekzadeh, Arjan, Leurs, Cyra, van Wieringen, Wessel, Steenwijk, Martijn D., Schoonheim, Menno M., Amann, Michael, Naegelin, Yvonne, Kuhle, Jens, Killestein, Joep, Teunissen, Charlotte E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651845/ https://www.ncbi.nlm.nih.gov/pubmed/31364818 http://dx.doi.org/10.1002/acn3.771 |
Ejemplares similares
-
No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018) -
Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017) -
Dynamic functional connectivity as a neural correlate of fatigue in multiple sclerosis
por: Tijhuis, Floris B., et al.
Publicado: (2021) -
Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis
por: Sestito, Claudia, et al.
Publicado: (2021) -
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)